碳青黴烯類抗藥性鮑氏不動桿菌(Carbapenem-Resistant Acinetobacter baumannii, CRAB),此類格蘭氏陰性菌(Gram-negative bacteria)的能透過感染人體引起敗血症、肺炎、腦膜炎、腹膜炎、心內膜炎,並因易產生抗藥性對於醫院中的患者具有很高的殺傷力,因為通常醫院治療細菌性敗血症的主要方式就是給予靜脈輸液及抗生素治療。2024年1月3日,瑞士羅氏製藥公司研究與開發中心的科學家於頂級期刊自然(nature)上發表了關於能阻斷CRAB菌株脂多醣(Lipopolysaccharide, LPS),進而使其失去構成桿菌細胞外膜能力死亡的抗生素,名為Zosurabalpin,並且已開始進行第一期的人體臨床試驗,有望作為新型突破性藥物。
References:
1. A novel antibiotic class targeting the lipopolysaccharide transporter(2024)
https://www.nature.com/articles/s41586-023-06873-0
https://www.nature.com/articles/s41586-023-06873-0
2. Zosurabalpin Compound Summary(2024)
3.‘Scientific breakthrough’leads to discovery of first antibiotic that kills drug-resistant bacteria in 50 years(2024)
https://nypost.com/2024/01/06/lifestyle/new-antibiotic-kills-deadly-drug-resistant-bacteria-in-scientific-breakthrough/
https://nypost.com/2024/01/06/lifestyle/new-antibiotic-kills-deadly-drug-resistant-bacteria-in-scientific-breakthrough/
4. 衛福部CRAB防治手冊(2015)
https://www.cdc.gov.tw/Uploads/68957076-e86b-4349-ae38-792aba1d6868.pdf
https://www.cdc.gov.tw/Uploads/68957076-e86b-4349-ae38-792aba1d6868.pdf
5. 碳青黴烯類抗藥性鮑氏不動桿菌在台灣之現況(2010)
https://www.airitilibrary.com/Article/Detail/10137653-201009-201102170028-201102170028-81-87
https://www.airitilibrary.com/Article/Detail/10137653-201009-201102170028-201102170028-81-87